Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04387773 · ClinicalTrials.gov registry record · Phase 4

Effect of GOCOVRI (Amantadine, Extended Release Capsules) on Gait in Parkinson's Disease

A Phase 4 study of Parkinson Disease, sponsored by Oregon Health and Science University.

Completed
Registry status
Phase 4
Development phase
8
Enrollment target
1
Study location

NCT04387773 is a Phase 4 study of Parkinson Disease that has completed, run by Oregon Health and Science University. The registered enrollment target is 8 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04387773, a Phase 4 study of Parkinson Disease, has completed, sponsored by Oregon Health and Science University.

COMPLETED
Registry status
Phase 4
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to learn about the effect of GOCOVRI (Amantadine extended release) on activity levels and measures of gait and balance quality in people with Parkinson's disease (PD) and levodopa induced dyskinesia (LID) during daily activities using body-worn sensors.

Conditions Studied

Parkinson Disease

Interventions

  • DRUG GOCOVRI

Study Locations (1)

Oregon

  • Oregon Health & Science University - Portland

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2020-11-05
Est. Completion 2022-09-30
Phase Phase 4

Sponsor

Oregon Health and Science University

546 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04387773

The ClinicalTrials.gov registry entry for NCT04387773 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (100% lower). The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which GOCOVRI is the first listed.

NCT04387773 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.

Frequently Asked Questions

What is clinical trial NCT04387773 about?

NCT04387773 is a clinical study titled "Effect of GOCOVRI (Amantadine, Extended Release Capsules) on Gait in Parkinson's Disease". The purpose of the study is to learn about the effect of GOCOVRI (Amantadine extended release) on activity levels and measures of gait and balance quality in people with Parkinson's disease (PD) and levodopa induced dyskinesia (LID) during daily activities using body-worn sensors.

What is the current status of trial NCT04387773?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 8 participants. The study started on 2020-11-05. Estimated completion is 2022-09-30.

What conditions does trial NCT04387773 study?

This clinical trial studies the following conditions: Parkinson Disease.

What interventions are being tested in trial NCT04387773?

The interventions under investigation include: GOCOVRI (DRUG).

Who is sponsoring clinical trial NCT04387773?

This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04387773 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Parkinson Disease

All registered trials for this condition

Oregon

All trials with a study site in Oregon

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.